trial

Study of Efficacy of PEAR-004 in Schizophrenia

NCTId NCT03751280
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 112 (actual)
Sponsored by Novartis Pharmaceuticals
Primary completion 2019-09-26
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
112 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2018-12-10
Primary completion
2019-09-26
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
PEAR-004

Sponsors

Novartis PharmaceuticalsLead Sponsor

Sites

6 total
Garden Grove, United StatesOakland, United StatesTorrance, United StatesMaitland, United StatesGrand Rapids, United StatesAlbuquerque, United States

Linked catalysts

1
Study of Efficacy of PEAR-004 in Schizophrenia — primary completion2019-09-26

Facts & assertions

4 sourced
Enrollment
112
Phase
PHASE2
Primary Completion Date
2019-09-26
Status
COMPLETED
relationships
The graph out of here
drug
PEAR-004
drug
lead_sponsor
Novartis Pharmaceuticals
company
indication
Hallucinations
indication
Paranoid Disorders
indication
Psychotic Disorders
indication